These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1657114)

  • 1. The antiemetic effect of granisetron in lower hemibody radiotherapy.
    Logue JP; Magee B; Hunter RD; Murdoch RD
    Clin Oncol (R Coll Radiol); 1991 Sep; 3(5):247-9. PubMed ID: 1657114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis.
    Belkacémi Y; Ozsahin M; Pène F; Rio B; Sutton L; Laporte JP; Touboul E; Gorin NC; Laugier A
    Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):77-82. PubMed ID: 8823261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of granisetron per os in radiotherapy-induced emesis].
    Krengli M; Lazzari R; Manara M
    Minerva Med; 1996 Dec; 87(12):605-8. PubMed ID: 9064597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
    Feyer P; Seegenschmiedt MH; Steingraeber M
    Support Care Cancer; 2005 Sep; 13(9):671-8. PubMed ID: 16044252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.
    Joss RA; Dott CS
    Eur J Cancer; 1993; 29A Suppl 1():S22-9. PubMed ID: 8381293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
    Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
    Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous granisetron with metoclopramide in the treatment of chemotherapy-induced emesis.
    Chiou TJ; Wei CH; Hsieh RK; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jul; 56(1):23-30. PubMed ID: 7553406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group.
    Kamanabrou D
    Eur J Cancer; 1992; 28A Suppl 1():S6-11. PubMed ID: 1320919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
    Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
    Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.